Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy.

Klement RJ, Sonke JJ, Allgäuer M, Andratschke N, Appold S, Belderbos J, Belka C, Dieckmann K, Eich HT, Flentje M, Grills I, Eble M, Hope A, Grosu AL, Semrau S, Sweeney RA, Hörner-Rieber J, Werner-Wasik M, Engenhart-Cabillic R, Ye H, Guckenberger M.

Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)32998-6. doi: 10.1016/j.radonc.2019.07.008. [Epub ahead of print]

PMID:
31431371
2.

Dynamic Enhancer DNA Methylation as Basis for Transcriptional and Cellular Heterogeneity of ESCs.

Song Y, van den Berg PR, Markoulaki S, Soldner F, Dall'Agnese A, Henninger JE, Drotar J, Rosenau N, Cohen MA, Young RA, Semrau S, Stelzer Y, Jaenisch R.

Mol Cell. 2019 Sep 5;75(5):905-920.e6. doi: 10.1016/j.molcel.2019.06.045. Epub 2019 Aug 15.

PMID:
31422875
4.

Salivary gland carcinoma (SGC) with perineural spread and/or positive resection margin - high locoregional control rates after photon (chemo) radiotherapy - experience from a monocentric analysis.

Haderlein M, Scherl C, Semrau S, Lettmaier S, Hecht M, Putz F, Iro H, Agaimy A, Fietkau R.

Radiat Oncol. 2019 Apr 23;14(1):68. doi: 10.1186/s13014-019-1260-x.

5.

Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report.

Semrau S, Agaimy A, Pavel M, Lubgan D, Schmidt D, Cavallaro A, Golcher H, Grützmann R, Fietkau R.

J Med Case Rep. 2019 Mar 23;13(1):82. doi: 10.1186/s13256-019-1995-x.

6.

Time course of pain response and toxicity after whole-nerve-encompassing LINAC-based stereotactic radiosurgery for trigeminal neuralgia-a prospective observational study.

Koca S, Distel L, Lubgan D, Weissmann T, Lambrecht U, Lang-Welzenbach M, Eyüpoglu I, Bischoff B, Buchfelder M, Semrau S, Fietkau R, Lettmaier S, Putz F.

Strahlenther Onkol. 2019 Aug;195(8):745-755. doi: 10.1007/s00066-019-01450-9. Epub 2019 Mar 15.

PMID:
30877350
7.

[FOLFIRINOX after resection of pancreatic cancer sets new standards-systemic therapy providing an impulse for local treatment in resectable pancreatic cancer].

Semrau S, Lubgan D.

Strahlenther Onkol. 2019 Jun;195(6):570-572. doi: 10.1007/s00066-019-01449-2. German. No abstract available.

PMID:
30847534
8.

[In HPV-associated oropharyngeal cancer, chemoradiotherapy with cisplatin is superior to bioradiotherapy with cetuximab in terms of overall survival].

Semrau S.

Strahlenther Onkol. 2019 May;195(5):447-449. doi: 10.1007/s00066-019-01441-w. German. No abstract available.

PMID:
30789992
9.

Single-cell transcriptomics reveals gene expression dynamics of human fetal kidney development.

Hochane M, van den Berg PR, Fan X, Bérenger-Currias N, Adegeest E, Bialecka M, Nieveen M, Menschaart M, Chuva de Sousa Lopes SM, Semrau S.

PLoS Biol. 2019 Feb 21;17(2):e3000152. doi: 10.1371/journal.pbio.3000152. eCollection 2019 Feb.

10.
11.

Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.

Ott OJ, Schmidt M, Semrau S, Strnad V, Matzel KE, Schneider I, Raptis D, Uter W, Grützmann R, Fietkau R.

Strahlenther Onkol. 2019 Jul;195(7):607-614. doi: 10.1007/s00066-018-1396-x. Epub 2018 Nov 2.

PMID:
30390114
12.

Repeating of local therapy of distant metastases increases overall survival in patients with synchronous metastasized rectal cancer-a monocentric analysis.

Haderlein M, Lettmaier S, Langheinrich M, Schmid A, Semrau S, Hecht M, Beck M, Schmidt D, Grützmann R, Fietkau R, Denz A.

Int J Colorectal Dis. 2018 Nov;33(11):1533-1541. doi: 10.1007/s00384-018-3113-8. Epub 2018 Jul 2.

PMID:
29968021
13.

The influence of tumour site on prognosis in metastatic colorectal carcinomas with primary tumour resection.

Merkel S, Schellerer VS, Wein A, Semrau S, Geppert C, Göhl J, Hohenberger W, Weber K, Grützmann R.

Int J Colorectal Dis. 2018 Sep;33(9):1215-1223. doi: 10.1007/s00384-018-3098-3. Epub 2018 Jun 18.

PMID:
29915904
14.

Allele-specific repression of Sox2 through the long non-coding RNA Sox2ot.

Messemaker TC, van Leeuwen SM, van den Berg PR, 't Jong AEJ, Palstra RJ, Hoeben RC, Semrau S, Mikkers HMM.

Sci Rep. 2018 Jan 10;8(1):386. doi: 10.1038/s41598-017-18649-4.

15.

Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety.

Grafe C, Semrau S, Hein A, Beckmann MW, Mackensen A, Dörje F, Fromm MF.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Feb;391(2):219-229. doi: 10.1007/s00210-017-1456-2. Epub 2018 Jan 2.

PMID:
29294142
16.

Sinonasal Leiomyosarcoma: Clinicopathological Analysis of Nine Cases with Emphasis on Common Association with Other Malignancies and Late Distant Metastasis.

Agaimy A, Semrau S, Koch M, Thompson LDR.

Head Neck Pathol. 2018 Dec;12(4):463-470. doi: 10.1007/s12105-017-0876-0. Epub 2017 Dec 21.

17.

Dynamics of lineage commitment revealed by single-cell transcriptomics of differentiating embryonic stem cells.

Semrau S, Goldmann JE, Soumillon M, Mikkelsen TS, Jaenisch R, van Oudenaarden A.

Nat Commun. 2017 Oct 23;8(1):1096. doi: 10.1038/s41467-017-01076-4.

18.

Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.

Haderlein M, Scherl C, Semrau S, Lettmaier S, Hecht M, Erber R, Iro H, Fietkau R, Agaimy A.

Strahlenther Onkol. 2017 Nov;193(11):961-970. doi: 10.1007/s00066-017-1196-8. Epub 2017 Aug 21.

PMID:
28828496
19.

Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma.

Lubgan D, Rutzner S, Lambrecht U, Rössler K, Buchfelder M, Eyüpoglu I, Fietkau R, Semrau S.

J Neurooncol. 2017 Sep;134(2):407-416. doi: 10.1007/s11060-017-2540-7. Epub 2017 Jun 30.

PMID:
28667597
20.

SMARCB1 (INI-1)-deficient Sinonasal Carcinoma: A Series of 39 Cases Expanding the Morphologic and Clinicopathologic Spectrum of a Recently Described Entity.

Agaimy A, Hartmann A, Antonescu CR, Chiosea SI, El-Mofty SK, Geddert H, Iro H, Lewis JS Jr, Märkl B, Mills SE, Riener MO, Robertson T, Sandison A, Semrau S, Simpson RH, Stelow E, Westra WH, Bishop JA.

Am J Surg Pathol. 2017 Apr;41(4):458-471. doi: 10.1097/PAS.0000000000000797.

21.

Stereotactic radiotherapy of vestibular schwannoma : Hearing preservation, vestibular function, and local control following primary and salvage radiotherapy.

Putz F, Müller J, Wimmer C, Goerig N, Knippen S, Iro H, Grundtner P, Eyüpoglu I, Rössler K, Semrau S, Fietkau R, Lettmaier S.

Strahlenther Onkol. 2017 Mar;193(3):200-212. doi: 10.1007/s00066-016-1086-5. Epub 2016 Dec 7.

PMID:
27928625
22.

Improved survival for elderly married glioblastoma patients : Better treatment delivery, less toxicity, and fewer disease complications.

Putz F, Putz T, Goerig N, Knippen S, Gryc T, Eyüpoglu I, Rössler K, Semrau S, Lettmaier S, Fietkau R.

Strahlenther Onkol. 2016 Nov;192(11):797-805. Epub 2016 Sep 14.

PMID:
27628965
23.

Predictors for occlusion of cerebral AVMs following radiation therapy : Radiation dose and prior embolization, but not Spetzler-Martin grade.

Knippen S, Putz F, Semrau S, Lambrecht U, Knippen A, Buchfelder M, Schlaffer S, Struffert T, Fietkau R.

Strahlenther Onkol. 2017 Mar;193(3):185-191. doi: 10.1007/s00066-016-1056-y. Epub 2016 Oct 18.

PMID:
27757503
24.

Management of advanced hypopharyngeal and laryngeal cancer with and without cartilage invasion.

Scherl C, Mantsopoulos K, Semrau S, Fietkau R, Kapsreiter M, Koch M, Traxdorf M, Grundtner P, Iro H.

Auris Nasus Larynx. 2017 Jun;44(3):333-339. doi: 10.1016/j.anl.2016.08.002. Epub 2016 Aug 25.

PMID:
27569289
25.

Frequent occurrence of therapeutically reversible CMV-associated encephalopathy during radiotherapy of the brain.

Goerig NL, Frey B, Korn K, Fleckenstein B, Überla K, Schmidt MA, Dörfler A, Engelhorn T, Eyüpoglu I, Rühle PF, Putz F, Semrau S, Gaipl US, Fietkau R.

Neuro Oncol. 2016 Dec;18(12):1664-1672. Epub 2016 Jun 10.

26.

Clinically significant CMV (re)activation during or after radiotherapy/chemotherapy of the brain : Correlation with neurological deterioration and improvement upon antiviral treatment.

Goerig N, Semrau S, Frey B, Korn K, Fleckenstein B, Überla K, Dörfler A, Putz F, Gaipl US, Fietkau R.

Strahlenther Onkol. 2016 Jul;192(7):489-97. doi: 10.1007/s00066-016-0987-7. Epub 2016 May 31.

PMID:
27245820
27.

Distant metastases in colorectal carcinoma: A proposal for a new M1 subclassification.

Merkel S, Weber K, Croner RS, Golcher H, Göhl J, Agaimy A, Semrau S, Siebler J, Wein A, Hohenberger W, Wittekind C.

Eur J Surg Oncol. 2016 Sep;42(9):1337-42. doi: 10.1016/j.ejso.2016.03.034. Epub 2016 Apr 19.

PMID:
27160353
28.

Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases.

Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Flentje M, Ganswindt U, Hass P, Henkenberens C, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Schmitt V, Semrau S, Sterzing F, Streblow J, Wendt TG, Wittig A, Guckenberger M.

Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):841-9. doi: 10.1016/j.ijrobp.2015.12.004. Epub 2015 Dec 15.

PMID:
26972657
29.

Recurrent glioblastoma: who receives tumor specific treatment and how often?

Steffens R, Semrau S, Lahmer G, Putz F, Lettmaier S, Eyüpoglu I, Buchfelder M, Fietkau R.

J Neurooncol. 2016 May;128(1):85-92. doi: 10.1007/s11060-016-2079-z. Epub 2016 Feb 23.

PMID:
26907492
30.

High-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype.

Haderlein M, Scherl C, Semrau S, Lettmaier S, Uter W, Neukam FW, Iro H, Agaimy A, Fietkau R.

Head Neck. 2016 Apr;38 Suppl 1:E2041-8. doi: 10.1002/hed.24375. Epub 2016 Feb 3.

PMID:
26841273
31.

Erratum to: Primary glioblastoma multiforme tumors and recurrence: comparative analysis of the danger signals HMGB1, HSP70, and calreticulin.

Muth C, Rubner Y, Semrau S, Rühle PF, Frey B, Strnad A, Buslei R, Fietkau R, Gaipl US.

Strahlenther Onkol. 2016 Mar;192(3):156. doi: 10.1007/s00066-016-0942-7. No abstract available.

PMID:
26809739
32.

BMP-SMAD Signaling Regulates Lineage Priming, but Is Dispensable for Self-Renewal in Mouse Embryonic Stem Cells.

Gomes Fernandes M, Dries R, Roost MS, Semrau S, de Melo Bernardo A, Davis RP, Ramakrishnan R, Szuhai K, Maas E, Umans L, Abon Escalona V, Salvatori D, Deforce D, Van Criekinge W, Huylebroeck D, Mummery C, Zwijsen A, de Sousa Lopes SM.

Stem Cell Reports. 2016 Jan 12;6(1):85-94. doi: 10.1016/j.stemcr.2015.11.012. Epub 2015 Dec 17.

33.

Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience.

Stubbe F, Agaimy A, Ott O, Lettmaier S, Vassos N, Croner R, Hohenberger W, Fietkau R, Semrau S.

Cancer Radiother. 2016 Feb;20(1):6-13. doi: 10.1016/j.canrad.2015.05.032. Epub 2015 Dec 11.

PMID:
26700874
34.

Primary glioblastoma multiforme tumors and recurrence : Comparative analysis of the danger signals HMGB1, HSP70, and calreticulin.

Muth C, Rubner Y, Semrau S, Rühle PF, Frey B, Strnad A, Buslei R, Fietkau R, Gaipl US.

Strahlenther Onkol. 2016 Mar;192(3):146-55. doi: 10.1007/s00066-015-0926-z. Epub 2015 Dec 8. Erratum in: Strahlenther Onkol. 2016 Mar;192(3):156.

PMID:
26646311
35.

Studying lineage decision-making in vitro: emerging concepts and novel tools.

Semrau S, van Oudenaarden A.

Annu Rev Cell Dev Biol. 2015;31:317-45. doi: 10.1146/annurev-cellbio-100814-125300. Review.

PMID:
26566114
36.

Differential Stoichiometry among Core Ribosomal Proteins.

Slavov N, Semrau S, Airoldi E, Budnik B, van Oudenaarden A.

Cell Rep. 2015 Nov 3;13(5):865-73. doi: 10.1016/j.celrep.2015.09.056. Epub 2015 Oct 22.

37.

Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy.

Guckenberger M, Klement RJ, Allgäuer M, Andratschke N, Blanck O, Boda-Heggemann J, Dieckmann K, Duma M, Ernst I, Ganswindt U, Hass P, Henkenberens C, Holy R, Imhoff D, Kahl HK, Krempien R, Lohaus F, Nestle U, Nevinny-Stickel M, Petersen C, Semrau S, Streblow J, Wendt TG, Wittig A, Flentje M, Sterzing F.

Radiother Oncol. 2016 Mar;118(3):485-91. doi: 10.1016/j.radonc.2015.09.008. Epub 2015 Sep 15.

PMID:
26385265
38.

Intra-abdominal ALK-positive anaplastic large cell lymphoma in a patient with neurofibromatosis type 1.

Agaimy A, Semrau S, Heinz M.

Histopathology. 2016 Apr;68(5):752-4. doi: 10.1111/his.12810. Epub 2015 Oct 16. No abstract available.

PMID:
26272700
39.

A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65.

Putz F, Knippen S, Lahmer G, Fietkau R, Semrau S.

Am J Clin Oncol. 2017 Oct;40(5):523-529. doi: 10.1097/COC.0000000000000198.

PMID:
26017481
40.

Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients.

Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, Gleisner S, Schulze B, Goldinger SM, Berking C, Forschner A, Clemens P, Grabenbauer G, Müller-Brenne T, Bauch J, Eich HT, Grabbe S, Schadendorf D, Schuler G, Keikavoussi P, Semrau S, Fietkau R, Distel LV, Heinzerling L.

Ann Oncol. 2015 Jun;26(6):1238-44. doi: 10.1093/annonc/mdv139. Epub 2015 Mar 11.

PMID:
25762352
41.

Single-cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: what are the best predictors of remission and prognosis?

Semrau S, Haderlein M, Schmidt D, Lell M, Wolf W, Waldfahrer F, Uder M, Iro H, Kuwert T, Fietkau R.

Cancer. 2015 Apr 15;121(8):1214-22. doi: 10.1002/cncr.29188. Epub 2014 Dec 23.

42.

Effective local control of vertebral metastases by simultaneous integrated boost radiotherapy: preliminary results.

Lubgan D, Ziegaus A, Semrau S, Lambrecht U, Lettmaier S, Fietkau R.

Strahlenther Onkol. 2015 Mar;191(3):264-71. doi: 10.1007/s00066-014-0780-4. Epub 2014 Nov 14.

PMID:
25395089
43.

Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis.

Schanne DH, Nestle U, Allgäuer M, Andratschke N, Appold S, Dieckmann U, Ernst I, Ganswindt U, Grosu AL, Holy R, Molls M, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Guckenberger M.

Strahlenther Onkol. 2015 Feb;191(2):125-32. doi: 10.1007/s00066-014-0739-5. Epub 2014 Aug 27.

PMID:
25159135
44.

Older patients with inoperable non-small cell lung cancer: long-term survival after concurrent chemoradiotherapy.

Semrau S, Zettl H, Hildebrandt G, Klautke G, Fietkau R.

Strahlenther Onkol. 2014 Nov;190(12):1125-32. doi: 10.1007/s00066-014-0710-5. Epub 2014 Aug 7.

PMID:
25098688
45.

Sporadic endolymphatic sac tumor--a diagnostic and therapeutic challenge.

Künzel J, Agaimy A, Hornung J, Lell M, Ganslandt O, Semrau S, Zenk J.

Int J Clin Exp Pathol. 2014 Apr 15;7(5):2641-6. eCollection 2014.

46.

Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy.

Merten R, Hecht M, Haderlein M, Distel L, Fietkau R, Heinzerling L, Semrau S.

Strahlenther Onkol. 2014 Nov;190(12):1169-72. doi: 10.1007/s00066-014-0698-x. Epub 2014 Jun 26.

PMID:
24965480
47.

SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms.

Agaimy A, Koch M, Lell M, Semrau S, Dudek W, Wachter DL, Knöll A, Iro H, Haller F, Hartmann A.

Am J Surg Pathol. 2014 Sep;38(9):1274-81. doi: 10.1097/PAS.0000000000000236.

48.

[Oligometastatic non-small cell lung cancer--surgical options and therapy strategies].

Schreiner W, Semrau S, Fietkau R, Sirbu H.

Zentralbl Chir. 2014 Jun;139(3):335-41. doi: 10.1055/s-0034-1368233. Epub 2014 May 8. German.

PMID:
24810892
49.

Transcriptional profiling of cells sorted by RNA abundance.

Klemm S, Semrau S, Wiebrands K, Mooijman D, Faddah DA, Jaenisch R, van Oudenaarden A.

Nat Methods. 2014 May;11(5):549-551. doi: 10.1038/nmeth.2910. Epub 2014 Mar 30.

50.

Temozolomide-induced liver damage. A case report.

Becker F, Hecht M, Schmidtner J, Semrau S, Fietkau R.

Strahlenther Onkol. 2014 Apr;190(4):408-10. doi: 10.1007/s00066-013-0519-7. Epub 2014 Jan 24.

PMID:
24452817

Supplemental Content

Loading ...
Support Center